NCT04228354View on ClinicalTrials.gov

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions

Healthy VolunteersOverweightObesity

Interventions

DRUG

Semaglutide

Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss